Brand–brand competition unlikely to lower list prices of brand-name drugs
Greater brand–brand competition alone will likely not lower list prices of brand-name drugs in the US, according to a study published July 30 in the open-access journal PLOS Medicine by Ameet Sarpatwari of Brigham and Women’s Hospital and Harvard Medical School, and colleagues.
No hay comentarios:
Publicar un comentario